H2R, I think you misunderstood. I meant Teva/Antares has more competition. I posted those articles to give background about the epinephrine competition and to point out (for those that might not know) that Teva/Antares are producing the only AB rated generic (the only easily substituted EpiPen) which is not just another generic epinephrine product like Amneal’s Adrenaclick, Kale’s Auvi-Q and Adamis’ Symjepi syringe. In theory this rating should help Teva/Antares gain a greater market share from Mylan. I think ADMP’s Symjepi will take a very small market share.
Why, after years of waiting and a year of EpiPen shortages, (now that Teva/Antares finally got approved) suddenly there’s even more competition?
News 
Market Data 
Discover 
